Table 1.
Summary of targeted treatments in follicular lymphoma. Abbreviations: ORR, overall response rate; CR, complete response; PFS, progression-free survival; -, no additional agent; BTK, Bruton tyrosine kinase; PI3K, phosphatidylinositol-3-kinase; SYK, spleen tyrosine kinase; BR, bendamustine-rituximab; CAR, chimeric antigen receptor; CRS, cytokine-release syndrome; ICANS, immune effector cell-associated neurotoxicity syndrome.
| Class | Agent | Combination | Indication | Phase | ORR (CR) | Median PFS | Notable Adverse Events |
|---|---|---|---|---|---|---|---|
| BTK inhibitors | Ibrutinib | - | Relapsed | II [10] | 38% (13%) | 14mo | diarrhea, atrial fibrillation bleeding, rash |
| - | Relapsed | II [11] | 30% (11%) | 4.6mo | |||
| Rituximab | Upfront | II [12] | 85% (40%) | 42mo | |||
| Acalabrutinib | Rituximab | Upfront | Ib [13] | 92% (31%) | diarrhea | ||
| PI3K inhibitors | Idelalisib | - | Relapsed | II [14] | 56% (14%) | 11mo | hepatitis, colitis, transaminitis, pneumonitis |
| Copanlisib | - | Relapsed | II [15] | 59% (12%) | 11.2mo | Hyperglycemia, hypertension | |
| Duvelisib | - | Relapsed | II [16] | 42% (1%) | 9.5mo | diarrhea | |
| SYK inhibitors | Fostamatinib disodium | - | Relapsed | I/II [17] | 10% | 4.6mo | hematologic toxicity, diarrhea, |
| Entospletinib | - | Relapsed | II [18] | 17% (0%) | 5.7mo | ||
| Cerdulatinib | Rituximab | Relapsed | II [19] | 59% (12%) | lipase increase | ||
| Immunomodulatory agents | Lenalidomide | Rituximab | Upfront | III [20] | 61% (48%) | cutaneous reactions, diarrhea, hematologic toxicity | |
| Rituximab | Relapsed | III [21] | 78% (34%) | 39.4mo | |||
| Obinutuzumab | Upfront | II [22] | 98% (92%) | ||||
| Avadomide | Rituximab | Relapsed | Ib [23] | 65% (22%) | 6.3mo | ||
| EZH2 inhibitors | Tazemetostat | Relapsed | II [24] | 69% (13%) | 13.8mo | alopecia | |
| BCL2 inhibitors | Venetoclax | BR | Relapsed | II [25] | 84% (75%) | hematologic toxicity | |
| CAR T-cell | Axi-cel | - | Relapsed | II [26] | 95% (80%) | CRS, ICANS | |
| Tisa-cel | - | Relapsed | II [27] | 82% (65%) | |||
| T-cell engaging bispecific antibodies | Mosunetuzumab | - | Relapsed | I/Ib [28] | 68% (50%) | 11.8mo | CRS, ICANS |
| Odronextamab | - | Relapsed | I [29] | 93% (75%) | 12.8mo | ||
| Glofitamab | Obinutuzumab | Relapsed | I/Ib [30] | 100% (75%) | |||
| Epcoritamab | - | Relapsed | I/II [31] | 100% (67%) | |||
| Antibody-drug conjugates | Polatuzumab vedotin | Rituximab | Relapsed | II [32] | 70% (45%) | 15.3mo | neutropenia |
| Immune checkpoint inhibitors | Nivolumab | - | Relapsed | II [33] | 4% (1%) | 2.2mo | immune related adverse events |
| Pembrolizumab | Rituximab | Relapsed | II [34] | 64% (48%) | |||
| Pidilizumab | Rituximab | Relapsed | II [35] | 66% (52%) | 18.8mo | ||
| CD47 blockade | Rituximab | Relapsed | Ib [36] | 71% (43%) | anemia | ||
| Radio-immunotherapy | 90Y-ibritumomab tiuxetan | - | Relapsed | III [37] | 80% (30%) | 11.2mo | myelosuppression |